Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Jan. 25, 2024

Circulating tumor cells (CTCs), circulating DNA (ctDNA), and extracellular vehicles (EVs) have received significant attention in recent times as emerging biomarkers subjects of transformational studies. The three main branches liquid biopsy evolved from the primary detection targets—CTC, ctDNA, EVs—each with distinct benefits. CTCs are derived cancer original or metastases may display global features tumor. ctDNA has been extensively analyzed used to aid diagnosis, treatment, prognosis neoplastic diseases. EVs contain tumor-derived material such DNA, RNA, proteins, lipids, sugar structures, metabolites. provide different contents but strong complementarity a certain extent. Even though they already employed several clinical trials, utility is still being studied, promising initial findings. This review thoroughly overviews established technologies for isolation, characterization, content CTC, EVs. Also discussed were most developments study potential therapeutic monitoring, prediction. These included Finally, challenges employing based on precision medicine evaluated.

Language: Английский

---

Liquid biopsy: from concept to clinical application

Scientific Reports, Journal Year: 2023, Volume and Issue: 13(1)

Published: Dec. 7, 2023

The diagnosis and treatment of cancer presents a physical mental burden to the patient, often involving diagnostic biopsies surgeries or chemotherapeutic approaches with severe side-effects. Advances which enable early detection close monitoring disease course without invasive procedures, can underpin tailored approach treatment, therefore make big difference quality life patients. Liquid be used access tumor cells DNA circulating in blood. Monitoring these species provide minimally repeatable means detect cancer, gain information about its response treatment.

Language: Английский

---

Detection and Molecular Characterization of Circulating Tumour Cells: Challenges for the Clinical Setting

Cancers, Journal Year: 2023, Volume and Issue: 15(7), P. 2185 - 2185

Published: April 6, 2023

Over the last decade, liquid biopsy has gained much attention as a powerful tool in personalized medicine since it enables monitoring cancer evolution and follow-up of patients real time. Through minimally invasive procedures, provides important information through analysis circulating tumour cells (CTCs) tumour-derived material, such DNA (ctDNA), miRNAs (cfmiRNAs) extracellular vehicles (EVs). CTC already had an impact on prognosis, detection minimal residual disease (MRD), treatment selection patients. Numerous clinical trials nowadays include arm. is now exponentially expanding field almost all types solid cancers. Functional studies, mainly based CTC-derived cell-lines explants (CDx), provide insights into metastatic process. The purpose this review to summarize latest findings significance CTCs for management patients, covering four years. This focuses providing comprehensive overview breast, prostate non-small-cell lung cancer. unique potential single-cell understanding metastasis biology, importance quality control standardization methodologies used field, also discussed.

Language: Английский

---

Liquid Biopsy in the Clinical Management of Cancers

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(16), P. 8594 - 8594

Published: Aug. 6, 2024

Liquid biopsy, a noninvasive diagnosis that examines circulating tumor components in body fluids, is increasingly used cancer management. An overview of relevant literature emphasizes the current state liquid biopsy applications care. Biomarkers particularly DNA (ctDNA), RNAs (ctRNA), cells (CTCs), extracellular vesicles (EVs), and other components, offer promising opportunities for early diagnosis, treatment selection, monitoring, disease assessment. The implementation precision medicine has shown significant potential various types, including lung cancer, colorectal breast prostate cancer. Advances genomic molecular technologies such as next-generation sequencing (NGS) digital polymerase chain reaction (dPCR) have expanded utility enabling detection somatic variants actionable alterations tumors. also demonstrated predicting responses, monitoring minimal residual (MRD), assessing heterogeneity. Nevertheless, standardizing techniques, interpreting results, integrating them into clinical routine remain challenges. Despite these challenges, implications management, offering dynamic approach to understanding biology guiding personalized strategies.

Language: Английский

---

Circulating Tumor Cells: From Basic to Translational Research

Clinical Chemistry, Journal Year: 2024, Volume and Issue: 70(1), P. 81 - 89

Published: Jan. 1, 2024

Abstract Background Metastasis is the leading cause of cancer-related deaths. Most studies have focused on primary tumor or overt metastatic lesions, leaving a significant knowledge gap concerning blood-borne cancer cell dissemination, major step in cascade. Circulating cells (CTCs) blood patients with solid can now be enumerated and investigated at molecular level, giving unexpected information biology Content Here, we reviewed recent advances basic translational/clinical research CTCs as key elements Summary Findings from translational elucidated complexity process. Fully understanding this process will open new potential avenues for therapeutic diagnostic strategies to propose precision medicine all patients.

Language: Английский

---

Liquid biopsy: Cell-free DNA based analysis in breast cancer

The Journal of Liquid Biopsy, Journal Year: 2023, Volume and Issue: 1, P. 100002 - 100002

Published: July 27, 2023

Breast cancer management has witnessed significant advancements, especially in the diagnosis and treatment response monitoring through implementation of imaging techniques tissue biopsy procedures. Nevertheless, there is potential for further improvement by integrating less invasive approaches that offer timely precise information. Liquid biopsy, which involves isolating tumor-derived components such as circulating cell-free DNA (cfDNA) its subset known tumor (ctDNA), can greatly enhance prognosis, identification specific genomic alterations, selection targeted therapies breast patients. While incorporation ctDNA-based testing into clinical practice been primarily focused on metastatic (MBC), growing interest applicability early-stage given ability to capture heterogeneity. Additionally, minimally nature ctDNA allows multiple serial samplings, providing a dynamic assessment characteristics over time. However, analysis encounters challenge related abundance temporal aspect disease. The quantity relation disease stage poses an important obstacle often hinders accurate analysis. Therefore, it crucial ensure sample collection, employ sensitive detection methods, carefully manage pre-analytical phase overcome these challenges facilitate successful cancer. This article aims summarize methodologies employed ctDNA, provide comprehensive review current applications cancer, elucidate underlying rationale extension broader contexts. Furthermore, models could widespread adoption various healthcare institutions are discussed.

Language: Английский

---

Liquid Biopsy in Lung Cancer: Biomarkers for the Management of Recurrence and Metastasis

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(10), P. 8894 - 8894

Published: May 17, 2023

Liquid biopsies have emerged as a promising tool for the detection of metastases well local and regional recurrence in lung cancer. biopsy tests involve analyzing patient’s blood, urine, or other body fluids biomarkers, including circulating tumor cells tumor-derived DNA/RNA that been shed into bloodstream. Studies shown liquid can detect cancer with high accuracy sensitivity, even before they are visible on imaging scans. Such valuable early intervention personalized treatment, aiming to improve patient outcomes. also minimally invasive compared traditional tissue biopsies, which require removal sample further analysis. This makes more convenient less risky option patients, particularly those who not good candidates procedures due medical conditions. While relapse still being developed validated, hold great promise improving treatment this deadly disease. Herein, we summarize available novel approaches describe their applications clinical practice.

Language: Английский

---

Nanobiotechnology augmented cancer stem cell guided management of cancer: liquid-biopsy, imaging, and treatment

Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)

Published: April 12, 2024

Abstract Cancer stem cells (CSCs) represent both a key driving force and therapeutic target of tumoral carcinogenesis, tumor evolution, progression, recurrence. CSC-guided diagnosis, treatment, surveillance are strategically significant in improving cancer patients’ overall survival. Due to the heterogeneity plasticity CSCs, high sensitivity, specificity, outstanding targeting demanded for CSC detection targeting. Nanobiotechnologies, including biosensors, nano-probes, contrast enhancers, drug delivery systems, share identical features required. Implementing these techniques may facilitate performance In this review, we focus on some most recent advances how nanobiotechnologies leverage characteristics optimize diagnosis treatment liquid biopsy, clinical imaging, nano-treatment. Specifically, attributes maximize circulating DNA, cells, exosomes, improve positron emission computed tomography magnetic resonance enhance effects cytotoxic therapy, photodynamic immunotherapy radioimmunotherapy reviewed.

Language: Английский

---

Searching for the “Holy Grail” of breast cancer recurrence risk: a narrative review of the hunt for a better biomarker and the promise of circulating tumor DNA (ctDNA)

Breast Cancer Research and Treatment, Journal Year: 2024, Volume and Issue: 205(2), P. 211 - 226

Published: Feb. 15, 2024

Language: Английский

---

Circulating tumor cells et al.: towards a comprehensive liquid biopsy approach in breast cancer

Translational Breast Cancer Research, Journal Year: 2024, Volume and Issue: 5, P. 10 - 10

Published: April 1, 2024

Abstract: Liquid biopsy has emerged as a crucial tool in managing breast cancer (BC) patients, offering minimally invasive approach to detect circulating tumor biomarkers. Until recently, the majority of studies BC focused on evaluating single liquid analyte, primarily DNA and cells (CTCs). Despite proven prognostic predictive value CTCs, their low abundance when detected using enrichment methods, especially early stages, poses significant challenge. It is becoming evident that combining diverse biomarkers, each representing different facets biology, potential enhance management patients with BC. This article emphasizes importance considering these biomarkers complementary/synergistic rather than competitive, recognizing ability contribute comprehensive disease profile. The review provides an overview clinical significance simultaneously analyzing CTCs other including cell-free DNA, extracellular vesicles, non-canonical RNAs, non-malignant cells. Such holds promise not only but also types, opportunities for detection, prognostication, therapy monitoring. However, addressing associated challenges, such refining detection methods establishing standardized protocols, realizing full transforming our understanding As field evolves, collaborative efforts will be instrumental unlocking revolutionary impact research management.

Language: Английский

---